Cambridge, UK, 12 April – Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2023-04-12 12:00:462023-04-12 11:25:06Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
Co-founder and CEO Mike Romanos steps down after six years to take up role of Associate Dean of Enterprise in the Faculty of Medicine at Imperial College Tim Sharpington, Microbiotica COO and experienced industry executive, appointed new CEO Cambridge, UK, 29 November 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and […]
Cambridge, UK, 20 June 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, confirms its upcoming scientific conference attendance. Microbiome Movement – Drug Development, 21-24 June 2022, Boston, US Dr Ron Carter, Microbiotica’s CMO, will be contributing to a panel at Microbiome Movement – Drug Development, taking place in Boston, […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2022-06-20 09:00:302022-06-20 11:33:02Microbiotica to present at key industry conferences in Q3 2022
Collaboration with US-based non-profit underlines potential of Company’s ulcerative colitis work Cambridge, UK, 05 April 2022 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel […]
Funds Phase 1b clinical trials in immuno-oncology and ulcerative colitis and expansion of microbiome-based product pipeline to other indications Series B funding round co-led by new investors Tencent and Flerie Invest, with additional participation from British Patient Capital and existing investors Cambridge Innovation Capital, IP Group and Seventure Company on the trajectory to become […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2022-03-07 08:00:292022-03-04 17:16:26Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00Rasa Kirchovaitehttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngRasa Kirchovaite2021-06-23 12:56:462021-06-23 12:56:46Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
Read an exclusive interview with Microbiotica CEO Mike Romanos published by Microbiome Movement. The interview covers the exciting developments in the microbiome space, Microbiotica’s progress over the past year, and a forward look at the Company’s aims in the next 12 months.
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2021-05-05 10:38:562021-05-06 16:03:21Microbiome Movement Exclusive Interview with Mike Romanos
Cambridge, UK, 30 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards. The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include […]
All staff under one roof, at state-of-the-art office and laboratory space Cambridge, UK, 19 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. The Company’s operations were previously split between the Sulston […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00Rasa Kirchovaitehttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngRasa Kirchovaite2021-04-19 09:13:442021-05-05 11:03:29Microbiotica Moves Into New Building at Chesterford Research Park
Cambridge, UK, 24 February 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Hans Schikan as Non-Executive Chairman, effective immediately. Hans brings decades of commercial, development, transactional and leadership experience from the biopharma industry. He is a well-established biopharma leader, having held many board memberships on both private and […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2021-02-24 09:00:172021-02-24 08:36:29Microbiotica Appoints Hans Schikan as Independent Non-Executive Chairman
Find us on LinkedIn
info@microbiotica.com
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
/in News /by immunocityCambridge, UK, 12 April – Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, […]
Microbiotica announces transition of leadership
/in News /by immunocityCo-founder and CEO Mike Romanos steps down after six years to take up role of Associate Dean of Enterprise in the Faculty of Medicine at Imperial College Tim Sharpington, Microbiotica COO and experienced industry executive, appointed new CEO Cambridge, UK, 29 November 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and […]
Microbiotica to present at key industry conferences in Q3 2022
/in News /by immunocityCambridge, UK, 20 June 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, confirms its upcoming scientific conference attendance. Microbiome Movement – Drug Development, 21-24 June 2022, Boston, US Dr Ron Carter, Microbiotica’s CMO, will be contributing to a panel at Microbiome Movement – Drug Development, taking place in Boston, […]
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic
/in News /by immunocityCollaboration with US-based non-profit underlines potential of Company’s ulcerative colitis work Cambridge, UK, 05 April 2022 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel […]
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
/in News /by immunocity Funds Phase 1b clinical trials in immuno-oncology and ulcerative colitis and expansion of microbiome-based product pipeline to other indications Series B funding round co-led by new investors Tencent and Flerie Invest, with additional participation from British Patient Capital and existing investors Cambridge Innovation Capital, IP Group and Seventure Company on the trajectory to become […]
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
/in News, Sticky news /by Rasa KirchovaiteMB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, […]
Microbiome Movement Exclusive Interview with Mike Romanos
/in News /by immunocityRead an exclusive interview with Microbiotica CEO Mike Romanos published by Microbiome Movement. The interview covers the exciting developments in the microbiome space, Microbiotica’s progress over the past year, and a forward look at the Company’s aims in the next 12 months.
Microbiotica Highly Commended at Cambridge Independent Science and Technology Awards
/in News /by Rasa KirchovaiteCambridge, UK, 30 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards. The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include […]
Microbiotica Moves Into New Building at Chesterford Research Park
/in News /by Rasa KirchovaiteAll staff under one roof, at state-of-the-art office and laboratory space Cambridge, UK, 19 April 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. The Company’s operations were previously split between the Sulston […]
Microbiotica Appoints Hans Schikan as Independent Non-Executive Chairman
/in News /by immunocityCambridge, UK, 24 February 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Hans Schikan as Non-Executive Chairman, effective immediately. Hans brings decades of commercial, development, transactional and leadership experience from the biopharma industry. He is a well-established biopharma leader, having held many board memberships on both private and […]